Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.

Philippe GarciaAlexis RevetAntoine YrondiVanessa RousseauYannick DegboeFrançois Montastruc

Published in: Drug safety (2020)

This pharmacovigilance analysis suggests that COVID-19 patients exposed to hydroxychloroquine experienced serious psychiatric disorders, and, among these patients, some committed suicide. Further real-world studies are needed to quantify the psychiatric risk associated with hydroxychloroquine during the COVID-19 pandemic.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
mental health
peritoneal dialysis
emergency department
adverse drug